Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Corcept Therapeutics Incorporated

Healthcare US CORT

72.65USD
1.45(2.04%)

Last update at 2026-06-03T20:00:00Z

Day Range

70.0772.94
LowHigh

52 Week Range

28.6691.00
LowHigh

Fundamentals

  • Previous Close 71.20
  • Market Cap4841.79M
  • Volume788048
  • P/E Ratio56.38
  • Dividend Yield-%
  • EBITDA45.95M
  • Revenue TTM761.41M
  • Revenue Per Share TTM7.33
  • Gross Profit TTM 748.43M
  • Diluted EPS TTM0.80

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 66.46M 161.49M 124.56M 116.19M 125.01M
Minority interest - - - - -
Net income 99.65M 139.73M 106.14M 101.42M 112.51M
Selling general administrative 448.73M 280.32M 184.26M 152.85M 122.36M
Selling and marketing expenses - - - - -
Gross profit 748.43M 664.16M 475.89M 396.47M 360.70M
Reconciled depreciation 1.89M 1.34M 2.36M 2.97M 3.07M
Ebit 66.46M 136.95M 107.28M 109.67M 121.41M
Ebitda 68.35M 138.29M 108.32M 112.63M 124.48M
Depreciation and amortization 1.89M 1.34M 1.04M 2.97M 3.07M
Non operating income net other - - - - 0.53M
Operating income 44.80M 136.95M 107.28M 112.63M 124.48M
Other operating expenses 716.61M 538.09M 375.09M 289.22M 241.50M
Interest expense - - - 3.56M 3.60M
Tax provision -33.18900M 20.28M 18.42M 14.77M 12.49M
Interest income 21.67M 24.54M 17.27M 3.56M 0.53M
Net interest income 21.67M 24.54M 17.27M 3.56M 0.53M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -33.18900M 20.28M 18.42M 14.77M 12.49M
Total revenue 761.41M 675.04M 482.38M 401.86M 365.98M
Total operating expenses 703.63M 527.21M 368.61M 283.84M 236.22M
Cost of revenue 12.98M 10.88M 6.48M 5.38M 5.28M
Total other income expense net 21.67M 24.54M 17.27M 3.56M 0.53M
Discontinued operations - - - - -
Net income from continuing ops 99.65M 141.21M 106.14M 101.42M 112.51M
Net income applicable to common shares - - - 101.29M 112.51M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 836.65M 840.55M 621.52M 583.43M 423.76M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 40.66M 17.78M 27.56M 16.42M 10.31M
Total liab 188.85M 160.96M 114.81M 81.59M 47.95M
Total stockholder equity 647.80M 679.59M 506.70M 501.84M 375.81M
Deferred long term liab - - - - -
Other current liab 109.38M 124.38M 0.65M 68.47M -0.52600M
Common stock 0.14M 0.14M 0.13M 0.13M 0.13M
Capital stock 0.14M 0.14M 0.13M 0.13M 0.13M
Retained earnings 643.39M 543.74M 402.53M 296.39M 194.97M
Other liab - - - 9.10M 0.41M
Good will - - - - -
Other assets - - - 77.45M 43.50M
Cash 120.50M 127.67M 135.55M 436.62M 335.81M
Cash and equivalents - - - - -
Total current liabilities 166.09M 140.77M 104.50M 81.59M 6.91M
Current deferred revenue - - 86.30M - -
Net debt -114.38800M -120.72900M -135.40000M -435.47600M -335.28600M
Short term debt 1.08M 0.83M 0.15M 1.14M 0.53M
Short long term debt - - - - -
Short long term debt total 6.11M 6.94M 0.15M 1.14M 0.53M
Other stockholder equity 2.01M 135.94M 103.44M 206.19M 180.94M
Property plant equipment - - - 1.78M 1.00M
Total current assets 485.46M 471.60M 458.64M 498.71M 381.39M
Long term investments 160.27M 219.83M 57.18M 4.95M 112.28M
Net tangible assets - - - 501.84M 375.81M
Short term investments 251.66M 255.67M 232.67M 365.34M 145.92M
Net receivables 59.79M 58.08M 55.12M 45.06M 27.62M
Long term debt - - - - -
Inventory 12.87M 12.41M 7.73M 17.03M 17.95M
Accounts payable 40.44M 15.38M 17.40M 11.98M 6.91M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.26M -0.21700M 0.61M -0.86900M -0.22700M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.13M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - 194.97M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 176.52M 10.19M 14.79M 17.17M 14.40M
Deferred long term asset charges - - - - -
Non current assets total 351.19M 368.95M 162.88M 84.72M 42.37M
Capital lease obligations 6.11M 6.94M 0.15M 1.14M 0.53M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 69.97M -177.60400M 56.57M -114.32700M 136.59M
Change to liabilities - - - 4.76M 1.63M
Total cashflows from investing activities 69.76M -177.60400M 90.91M -114.32700M 136.13M
Net borrowings - - - - -
Total cash from financing activities -220.36600M -28.34900M -148.72300M -17.28400M -302.59100M
Change to operating activities - - - -5.19600M 1.51M
Net income 98.17M 141.21M 106.14M 101.42M 112.51M
Change in cash -7.17000M -7.88600M 69.22M -11.28800M 1.43M
Begin period cash flow 127.67M 135.55M 66.33M 77.62M 76.19M
End period cash flow 120.50M 127.67M 135.55M 66.33M 77.62M
Total cash from operating activities 142.00M 198.07M 127.04M 120.32M 167.89M
Issuance of capital stock - - - - -
Depreciation 1.89M 1.34M 2.36M 2.97M 3.07M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory -7.48100M 0.30M 1.26M 1.20M 3.44M
Change to account receivables -5.81000M 1.15M -10.06600M -3.43200M -1.42700M
Sale purchase of stock -245.85600M -15.66400M -145.42800M 0.00000M -295.98500M
Other cashflows from financing activities 25.49M -22.30100M -3.29500M -21.66500M -6.60600M
Change to netincome - - - 9.92M 47.29M
Capital expenditures 0.21M 2.17M 0.14M 0.41M 0.47M
Change receivables - - - - -1.42700M
Cash flows other operating - - - - 3.37M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 1.43M
Change in working capital -27.56600M 45.30M 8.22M 6.02M -0.05700M
Stock based compensation 84.50M 61.35M 48.94M 42.44M 42.93M
Other non cash items -14.99900M -10.93800M -9.12800M 1.38M 5.09M
Free cash flow 141.78M 195.90M 126.90M 119.91M 167.42M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CORT
Corcept Therapeutics Incorporated		 1.45 2.04% 72.65 56.38 129.87 6.36 7.68 6.05 98.72
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. It also develops relacorilant, a selective cortisol modulator for patients with hypercortisolism; a selective cortisol modulator miricorilant, which is in Phase 1b trial for metabolic dysfunction-associated steatohepatitis; and a portfolio of proprietary selective cortisol modulators, such as relacorilant, nenocorilant, miricorilant, and dazucorilant for the treatment of Lou Gehrig's disease. The company was incorporated in 1998 and is headquartered in Redwood City, California.

Corcept Therapeutics Incorporated

101 Redwood Shores Parkway, Redwood City, CA, United States, 94065

Key Executives

Name Title Year Born
Dr. Joseph K. Belanoff M.D. Co-Founder, Pres, CEO & Director 1957
Mr. Atabak Mokari CFO & Treasurer 1977
Dr. Hazel Hunt Ph.D. Chief Scientific Officer 1960
Mr. Sean Maduck Pres of Corcept Endocrinology 1977
Mr. Gary Charles Robb Chief Bus. Officer & Sec. 1963
Mr. Joseph Douglas Lyon Chief Accounting Officer 1979
Ms. Amy Flood Chief HR & Communications Officer NA
Dr. William Guyer Pharm.D. Chief Devel. Officer 1968
Dr. Joseph K. Belanoff M.D. Co-Founder, President, CEO & Director 1957
Mr. Sean Maduck President of Endocrinology 1977

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.